Ticagrelor | Drug Guide - MedSchool
Sign up to start your free trial of MedSchool Premium!Get Started
 
Drug Guide
 
 
#
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
U
V
W
Z
 

Ticagrelor

Bookmark
  •  
    Oral
    Ticagrelor
    Brilinta 
     
    Directly inhibits P2Y12 receptors, and does not require enzymatic activation.
    • Mechanism of Action
    • Irreversibly inhibits the binding of adenosine diphosphate (ADP) to platelet P2Y₁₂ receptors, resulting in reduced platelet activation and aggregation.
    • Pharmacology
    • Directly inhibits P2Y12 receptors, and does not require enzymatic activation.

Clinical Use

    • Indications
    • Acute coronary syndrome (in conjunction with aspirin)
    • Prevention of in-stent thrombosis following percutaneous coronary intervention
    • Contraindications
    • Active bleeding
    • Intracranial haemorrhage
    • Adverse Effects
    • Haemorrhage.
 
Feedback